JP2010532381A - Ｒａｆキナーゼ阻害剤として有用な複素環式化合物 - Google Patents

Ｒａｆキナーゼ阻害剤として有用な複素環式化合物 Download PDF

Info

Publication number
JP2010532381A
JP2010532381A JP2010515223A JP2010515223A JP2010532381A JP 2010532381 A JP2010532381 A JP 2010532381A JP 2010515223 A JP2010515223 A JP 2010515223A JP 2010515223 A JP2010515223 A JP 2010515223A JP 2010532381 A JP2010532381 A JP 2010532381A
Authority
JP
Japan
Prior art keywords
compound
optionally substituted
mmol
nitrogen
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010515223A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010532381A5 (enExample
Inventor
ジェニファー コスロー，
ビン グアン，
アレクセイ イシチェンコ，
ジョン ホワード ジョーンズ，
グナナサンバンダム クマールエーベル，
アレクセイ ルゴフスコイ，
ハイルー ペン，
ノエル ポーウェル，
ブライアン レイムンド，
裕子 田中
ジェフリー ベッセルズ，
トーマス ウィン，
チリ シン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Inc
Biogen Idec Inc
Biogen Idec MA Inc
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, Biogen Idec Inc, Biogen Idec MA Inc, Biogen MA Inc filed Critical Biogen Inc
Publication of JP2010532381A publication Critical patent/JP2010532381A/ja
Publication of JP2010532381A5 publication Critical patent/JP2010532381A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2010515223A 2007-06-29 2008-06-30 Ｒａｆキナーゼ阻害剤として有用な複素環式化合物 Pending JP2010532381A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94731907P 2007-06-29 2007-06-29
PCT/US2008/068789 WO2009006404A2 (en) 2007-06-29 2008-06-30 Heterocyclic compounds useful as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2010532381A true JP2010532381A (ja) 2010-10-07
JP2010532381A5 JP2010532381A5 (enExample) 2012-07-26

Family

ID=40015666

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010515223A Pending JP2010532381A (ja) 2007-06-29 2008-06-30 Ｒａｆキナーゼ阻害剤として有用な複素環式化合物

Country Status (8)

Country Link
US (1) US7968536B2 (enExample)
EP (1) EP2167497A2 (enExample)
JP (1) JP2010532381A (enExample)
CN (1) CN101743242A (enExample)
AU (1) AU2008273017C1 (enExample)
CA (1) CA2694284A1 (enExample)
NZ (1) NZ582349A (enExample)
WO (1) WO2009006404A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106898779A (zh) * 2015-12-21 2017-06-27 斯沃奇集团研究和开发有限公司 用于金属/空气电池的正极和制造该正极的方法
JP2021512861A (ja) * 2018-02-01 2021-05-20 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP2023517519A (ja) * 2020-03-02 2023-04-26 シロナックス・リミテッド フェロトーシス阻害剤ジアリールアミンパラアセトアミド類

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI444379B (zh) * 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
CA2737472A1 (en) * 2008-09-26 2010-04-01 Boehringer Ingelheim International Gmbh Azaindazole compounds as ccr1 receptor antagonists
MX2011006997A (es) * 2008-12-30 2011-10-21 Sunesis Pharmaceuticals Inc Compuestos de heteroarilo utiles como inhibidores de cinasa de factor recombinante activado (raf).
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
ES2549502T3 (es) 2009-11-20 2015-10-28 Sk Chemicals Co., Ltd. Antagonistas de receptores de gonadoliberina, método de fabricación de los mismos, y composición farmacéutica que los contienen
WO2012142029A2 (en) 2011-04-10 2012-10-18 Florida A&M University Serms for the treatment of estrogen receptor-mediated disorders
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
EP2809659A1 (en) 2012-02-03 2014-12-10 Basf Se Fungicidal pyrimidine compounds
EP2825533B1 (en) 2012-03-13 2016-10-19 Basf Se Fungicidal pyrimidine compounds
CN102936251A (zh) * 2012-11-05 2013-02-20 上海毕得医药科技有限公司 一种吡咯并[2,3-d]嘧啶衍生物的制备方法
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
WO2014144747A1 (en) * 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
US9045477B2 (en) 2013-03-15 2015-06-02 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
WO2015036059A1 (en) 2013-09-16 2015-03-19 Basf Se Fungicidal pyrimidine compounds
CN105722833A (zh) 2013-09-16 2016-06-29 巴斯夫欧洲公司 杀真菌的嘧啶化合物
CN104761502A (zh) * 2014-01-03 2015-07-08 中国药科大学 苯并咪唑衍生物、其制法及医药用途
WO2015103901A1 (zh) * 2014-01-08 2015-07-16 上海交通大学医学院 硬脂酰氨基酸盐及其制备方法和应用
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
KR20170032456A (ko) * 2015-01-14 2017-03-22 가부시끼가이샤 도시바 비수 전해질 전지 및 전지 팩
JP2019196307A (ja) * 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環アミド化合物
EP3515446B1 (en) 2016-09-19 2023-12-20 Novartis AG Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
EP3579872A1 (en) 2017-02-10 2019-12-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway
CN106928152A (zh) * 2017-03-03 2017-07-07 符爱清 一种尿嘧啶的制备方法
CA3057969A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EA039880B1 (ru) * 2017-05-30 2022-03-23 Дот Терапьютикс-1, Инк. Способ получения оптически активного соединения
WO2019067623A1 (en) * 2017-09-27 2019-04-04 The Regents Of The University Of California POWERFUL ANTIVIRAL COMPOUNDS CONTAINING PYRIDINE
US11725185B2 (en) 2017-12-28 2023-08-15 University Of Houston System Stem cell culture systems for columnar epithelial stem cells, and uses related thereto
AU2020276695B2 (en) 2019-05-13 2025-12-18 Novartis Ag New crystalline forms of N-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2 (trifluoromethyl)isonicotinamide as RAF inhibitors for the treatment of cancer
US20230119479A1 (en) 2019-12-10 2023-04-20 Shionogi & Co., Ltd. A histone deacetylase inhibitor having a nitrogen-containing aromatic heterocyclyl group
AU2021314955A1 (en) * 2020-07-28 2023-03-30 Jazz Pharmaceuticals Ireland Limited Fused bicyclic Raf inhibitors and methods for use thereof
US12404242B2 (en) 2021-12-17 2025-09-02 Reglagene, Inc. Compositions and methods for making and using small molecules in the treatment of cancer
CN121240859A (zh) 2023-02-28 2025-12-30 瑞格拉基因有限公司 用于治疗健康状况的组合物和制备和使用小分子的方法
CN117567388B (zh) * 2023-11-14 2024-04-16 济南悟通生物科技有限公司 一种2-乙酰基-5-噻唑甲酸的合成方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505193A (ja) * 1996-12-02 2001-04-17 藤沢薬品工業株式会社 ベンズアミド誘導体
JP2004501146A (ja) * 2000-06-19 2004-01-15 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害薬として活性のチオフェン誘導体、その製造方法及びそれを含有する医薬組成物
JP2005511478A (ja) * 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
JP2005525341A (ja) * 2002-02-18 2005-08-25 アストラゼネカ・アクチエボラーグ 化学化合物
WO2006003378A1 (en) * 2004-07-01 2006-01-12 Astrazeneca Ab Azine-carboxamides as anti-cancer agent
WO2006036266A1 (en) * 2004-07-16 2006-04-06 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
WO2006065703A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5563158A (en) * 1993-12-28 1996-10-08 The Dupont Merck Pharmaceutical Company Aromatic compounds containing basic and acidic termini useful as fibrinogen receptor antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5840917A (en) * 1995-09-26 1998-11-24 Takeda Chemical Industries, Ltd. Phosphorylamides, their preparation and use
US5760028A (en) * 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
CA2240439A1 (en) 1995-12-22 1997-07-03 The Dupont Merck Pharmaceutical Company Novel integrin receptor antagonists
US5872136A (en) * 1996-04-03 1999-02-16 Merck & Co., Inc. Arylheteroaryl inhibitors of farnesyl-protein transferase
CA2249607A1 (en) 1996-04-03 1997-10-09 Neville J. Anthony Inhibitors of farnesyl-protein transferase
US5877182A (en) * 1996-09-13 1999-03-02 Merck & Co., Inc. Piperidines promote release of growth hormone
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
AU6422798A (en) 1997-03-25 1998-10-20 Takeda Chemical Industries Ltd. Stabilized urease inhibitor
US6214834B1 (en) * 1997-03-28 2001-04-10 Dupont Pharmaceuticals Company Integrin inhibitor prodrugs
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
EP0982030A3 (en) * 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
EP1058549A4 (en) * 1998-12-23 2003-11-12 Bristol Myers Squibb Pharma Co FACTOR Xa OR THROMBIN INHIBITORS
WO2000053602A1 (en) 1999-03-10 2000-09-14 Merck & Co., Inc. 6-azaindole compounds as antagonists of gonadotropin releasing hormone
EP1171135A4 (en) * 1999-03-10 2002-05-15 Merck & Co Inc 6-AZAINDOL COMPOUNDS AS AN ANTAGONISTS OF THE GONADOTROPIN RELEASING HORMONE
WO2000058300A1 (en) 1999-03-25 2000-10-05 Nissan Chemical Industries, Ltd. Chroman derivatives
US6127382A (en) * 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
JP2003514897A (ja) 1999-11-24 2003-04-22 シーオーアール セラピューティクス インコーポレイテッド ベータ−アミノ酸系、アスパラギン酸系およびジアミノプロピオン酸系Ｘａ因子阻害剤
GB0007245D0 (en) 2000-03-24 2000-05-17 Zeneca Ltd Chemical compounds
EP1296678A2 (en) 2000-06-21 2003-04-02 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
US7402585B2 (en) * 2001-12-24 2008-07-22 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases
US20040048866A1 (en) * 2002-03-08 2004-03-11 Teodozyj Kolasa Indazole derivatives that are activators of soluble guanylate cyclase
WO2003101444A1 (en) * 2002-05-29 2003-12-11 Millennium Pharmaceuticals, Inc. Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer
AU2003245669A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
EP1554269A1 (en) * 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
EP1400244A1 (en) * 2002-09-17 2004-03-24 Warner-Lambert Company LLC New spirocondensed quinazolinones and their use as phosphodiesterase inhibitors
EP1547585A4 (en) 2002-09-25 2008-05-14 Santen Pharmaceutical Co Ltd THERAPEUTIC AGENT AGAINST RHEUMA WITH A BENZAMIDE DERIVATIVE AS AN ACTIVE SUBSTANCE
JP2004161716A (ja) 2002-11-15 2004-06-10 Takeda Chem Ind Ltd Ｊｎｋ阻害剤
JP4847868B2 (ja) * 2003-05-14 2011-12-28 ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド 化合物、及び、アミロイドベータの調節におけるその使用
JP2004339159A (ja) 2003-05-16 2004-12-02 Sankyo Co Ltd ４−オキソキノリン誘導体を含有する医薬組成物
DE10328999B4 (de) 2003-06-27 2006-08-31 Lanxess Deutschland Gmbh Verfahren zur Herstellung von Metallkomplexpigmenten mit niedriger Dispergierhärte
WO2005012304A2 (en) * 2003-07-16 2005-02-10 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
WO2005012307A1 (en) * 2003-07-16 2005-02-10 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
CN100412066C (zh) * 2003-09-30 2008-08-20 Irm责任有限公司 用作蛋白激酶抑制剂的化合物和组合物
KR101164541B1 (ko) 2004-01-12 2012-07-10 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 선택적 키나제 저해제
WO2005072733A1 (en) 2004-01-20 2005-08-11 Millennium Pharmaceuticals, Inc. Dyarylurea compounds as chk-1 inhibitors
CA2584485C (en) 2004-10-20 2013-12-31 Resverlogix Corp. Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
EP1841760B1 (en) 2004-12-30 2011-08-10 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
WO2006076442A2 (en) * 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
TWI444379B (zh) * 2007-06-29 2014-07-11 Sunesis Pharmaceuticals Inc 有用於作為Ｒａｆ激酶抑制劑之化合物
MX2011006997A (es) 2008-12-30 2011-10-21 Sunesis Pharmaceuticals Inc Compuestos de heteroarilo utiles como inhibidores de cinasa de factor recombinante activado (raf).

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001505193A (ja) * 1996-12-02 2001-04-17 藤沢薬品工業株式会社 ベンズアミド誘導体
JP2004501146A (ja) * 2000-06-19 2004-01-15 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害薬として活性のチオフェン誘導体、その製造方法及びそれを含有する医薬組成物
JP2005511478A (ja) * 2001-04-03 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド Ｎ−置換非アリール複素環アミジル系ｎｍｄａ／ｎｒ２ｂ拮抗薬
JP2005525341A (ja) * 2002-02-18 2005-08-25 アストラゼネカ・アクチエボラーグ 化学化合物
WO2006003378A1 (en) * 2004-07-01 2006-01-12 Astrazeneca Ab Azine-carboxamides as anti-cancer agent
WO2006036266A1 (en) * 2004-07-16 2006-04-06 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
WO2006065703A1 (en) * 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106898779A (zh) * 2015-12-21 2017-06-27 斯沃奇集团研究和开发有限公司 用于金属/空气电池的正极和制造该正极的方法
CN106898779B (zh) * 2015-12-21 2020-05-12 斯沃奇集团研究和开发有限公司 用于金属/空气电池的正极和制造该正极的方法
JP2021512861A (ja) * 2018-02-01 2021-05-20 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP2022160635A (ja) * 2018-02-01 2022-10-19 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP7184383B2 (ja) 2018-02-01 2022-12-06 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP7590004B2 (ja) 2018-02-01 2024-11-26 ザ・ユニバーシティ・オブ・シドニー 抗癌性化合物
JP2023517519A (ja) * 2020-03-02 2023-04-26 シロナックス・リミテッド フェロトーシス阻害剤ジアリールアミンパラアセトアミド類
JP7807381B2 (ja) 2020-03-02 2026-01-27 シロナックス リミテッド． フェロトーシス阻害剤ジアリールアミンパラアセトアミド類

Also Published As

Publication number Publication date
WO2009006404A3 (en) 2009-07-30
US20090005359A1 (en) 2009-01-01
US7968536B2 (en) 2011-06-28
NZ582349A (en) 2012-06-29
EP2167497A2 (en) 2010-03-31
AU2008273017A1 (en) 2009-01-08
AU2008273017B2 (en) 2013-10-10
CA2694284A1 (en) 2009-01-08
AU2008273017C1 (en) 2014-02-13
WO2009006404A2 (en) 2009-01-08
CN101743242A (zh) 2010-06-16

Similar Documents

Publication Publication Date Title
JP5649445B2 (ja) Ｒａｆキナーゼ阻害剤として有用な化合物
JP2010532381A (ja) Ｒａｆキナーゼ阻害剤として有用な複素環式化合物
JP2012514044A (ja) Ｒａｆキナーゼ阻害剤として有用なヘテロアリール化合物
US10703748B2 (en) Diazanaphthalen-3-yl carboxamides and preparation and use thereof
KR20210105375A (ko) Cdk 저해제로서의 대환식 화합물, 이의 제조 방법, 및 의약에서의 이의 용도
TW200940544A (en) Inhibitors of PI3 kinase
WO2011123493A1 (en) Substituted pyrrolotriazines as protein kinase inhibitors
HK1143357A (en) Pyrimidine derivatives useful as raf kinase inhibitors
HK1143357B (en) Pyrimidine derivatives useful as raf kinase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110614

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120601

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130613

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130620

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130920

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140312